loader image
Saturday, February 22, 2025
43.4 F
McAllen
We Welcome your Press Release
- Advertisement -

Valley Baptist-Harlingen to Hold Trauma Designation Reception

Translate to Spanish or other 102 languages!

Mega Doctor News 

- Advertisement -

Level II Trauma Designation is the first and only in the Rio Grande Valley

HARLINGEN – Valley Baptist Medical Center-Harlingen will hold a reception in recognition of its recent Major (Level II) Trauma Designation on Thursday, March 15 from 5 – 7 p.m. in the Valley Baptist-Harlingen Woodward Conference Center.

The hospital’s trauma center has been designated by the Texas Department of State Health Services as a Major (Level II) Trauma Facility. This follows the center’s verification by the American College of Surgeons after a review and visit last October. The Valley Baptist Medical Center-Harlingen trauma center is the first and only Major Trauma Facility in the Rio Grande Valley.

- Advertisement -

Presentations regarding the designation will begin at 6 p.m., and speakers will include Valley Baptist Health System & Valley Baptist-Harlingen CEO Manny Vela, Valley Baptist-Harlingen Trauma Medical Director Dr. Hillary Chollet, Harlingen Mayor Chris Boswell, and Harlingen Chamber of Commerce President & CEO Chris Gonzales.

For more information, call (956) 389-1953 or (956) 873-1378.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

UPDATE: Measles Outbreak

Mega Doctor News Mega Doctor News  As of February 18, 2025, the Texas...

DHR Health Celebrates 100th Ion Robotic-Assisted Bronchoscopy

DHR Health, a leader in healthcare serving the Rio Grande Valley, announced today that Dr. Federico Vallejo, pulmonologist, has successfully performed his 100th Ion robotic-assisted bronchoscopy.

DHR Health: Pioneering Alzheimer’s Treatment Breakthrough South of San Antonio

DHR Health, a leader in healthcare innovation, proudly announced today its groundbreaking achievement as the first hospital south of San Antonio to successfully administer Leqembi, an FDA-approved medication for the early treatment of Alzheimer’s disease. This milestone demonstrates their expertise and is a significant advancement in healthcare for the Rio Grande Valley.

FDA Approves First CRISPR Gene Therapy to Treat Sickle Cell Disease

Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older.
- Advertisement -
×